NASDAQ:CRSP CRISPR Therapeutics Q3 2026 Earnings Date & Estimates $53.39 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$53.68 +0.29 (+0.54%) As of 10/9/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CRISPR Therapeutics is expected to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for November 3, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeAfter Market ClosesConference Call DateNovember 3, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from CRISPR Therapeutics in Q3 2026CRISPR Therapeutics is expected to post earnings of -$1.04 per share on revenue of $14.62 million. In the same quarter a year earlier CRISPR Therapeutics reported -$1.17 per share on revenue of $0.89 million. CRISPR Therapeutics last reported on August 3, 2026, posting -$0.94 per share and beating the -$1.19 consensus estimate. CRISPR Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$1.04Expected Revenue$14.62 millionPrior-Year EPS-$1.17Prior-Year Revenue$0.89 millionExpected Revenue Growth+1,544.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.94 (Beat by +$0.25)Last Quarter Revenue$10.18 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report CRISPR Therapeutics Q3 2026 Earnings FAQ When does CRISPR Therapeutics report Q3 2026 earnings? CRISPR Therapeutics (NASDAQ:CRSP) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is CRISPR Therapeutics' Q3 2026 earnings call? CRISPR Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for CRISPR Therapeutics? Analysts expect CRISPR Therapeutics to post earnings of -$1.04 per share for Q3 2026. How much revenue is CRISPR Therapeutics expected to report? The consensus revenue estimate for CRISPR Therapeutics is $14.62 million for Q3 2026. CRISPR Therapeutics Earnings HeadlinesBofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy RatingOctober 9 at 2:55 PM | marketscreener.comMCiti Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.October 9 at 2:55 PM | fool.comUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider sources say Elon Musk is developing a breakthrough technology he describes as '10x bigger than the largest product in history.' Nvidia's CEO has called it 'the next biggest opportunity after AI,' with potential lifetime sales reaching $20 trillion. A launch date of July 22nd is on the radar for early investors positioning ahead of the announcement. | StocksToTrade (Ad)CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 9 at 2:45 AM | americanbankingnews.comCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026October 8, 2026 | finance.yahoo.comCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026October 8, 2026 | globenewswire.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine. Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia. The therapy uses a patient’s own blood stem cells, which are edited outside the body and then reinfused. Founded in 2013, CRISPR Therapeutics conducts research and clinical development internationally, with operations and activities in North America and Europe. The company was co-founded by Emmanuelle Charpentier, Rodger Novak, and other scientists, and is led by Chief Executive Officer Samarth Kulkarni.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
